Dongwha Pharm Corporate Governance Report: Low Compliance Rate (47%), Highlighting Need for Improved Shareholder Rights and Transparency
Dongwha Pharm, founded in 1897 as Korea's first pharmaceutical company, manufactures products such as Gas Hwalmyeongso, Panchol, and Hucidine. Its market cap is approximately KRW 157.3 billion.
The disclosed corporate governance report shows that only 7 out of 15 key indicators are met, resulting in a 47% compliance rate. Notably, the shareholder meeting notice was sent only 2 weeks prior (instead of 4 weeks), and there is no formal CEO succession or enterprise risk management policy.
Dividend predictability improved from 2026, but the company does not annually notify shareholders of its dividend policy. Dividend per share for 2025 fell sharply to KRW 65 from KRW 180 in previous years.
The board comprises 8 members including 3 outside directors, but the CEO also serves as board chair, there is no female director, and cumulative voting is not adopted, indicating lack of diversity and shareholder democracy.
The audit committee is composed entirely of outside directors, ensuring independence, but internal control weaknesses include failure to hold quarterly meetings with external auditors without management presence.
[AI Summary]Dongwha Pharm's governance meets legal minimums but significantly lags best practices, potentially harming shareholder trust. The dividend cut, loss of board diversity, and absence of CEO succession and risk management policies are risks to long-term value creation, necessitating continuous improvement.